{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=24", "query": { "intervention": "antibody-drug conjugate", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 503, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T03:52:29.443Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03149549", "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Breast Cancer", "Non Small Cell Lung Cancer", "Head and Neck Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CX-2009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2017-06-01", "completion_date": "2020-09-10", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 16, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149549" }, { "nct_id": "NCT07145255", "title": "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer Castration-resistant Prostate Cancer", "Breast Cancer", "Colo-rectal Cancer", "Lung Cancer (Non-Small Cell)", "Pancreas Cancer, Duct Cell Adenocarcinoma" ], "interventions": [ { "name": "ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MBrace Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-09-03", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 7, "location_summary": "San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07145255" }, { "nct_id": "NCT06827236", "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Breast Cancer", "Unresectable Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BNT323", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2025-04-23", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 28, "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06827236" }, { "nct_id": "NCT05535244", "title": "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2022-10-17", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 9, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535244" }, { "nct_id": "NCT06555263", "title": "Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Lung Cancer Metastatic", "Lung Cancer, Nonsmall Cell", "Lung Cancer Non-Small Cell Stage IIIB", "Lung Cancer Non-small Cell Stage IV", "Lung Cancer, Non-small Cell" ], "interventions": [ { "name": "Luveltamab tazevibulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-08-21", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 7, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Lake Mary, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06555263" }, { "nct_id": "NCT04843709", "title": "A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "MRG004A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lepu Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2021-07-26", "completion_date": "2024-07-26", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 6, "location_summary": "Orange, California • New York, New York • Canton, Ohio + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843709" }, { "nct_id": "NCT01026233", "title": "Cardiac Safety Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026233" }, { "nct_id": "NCT00324831", "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "Intervention/procedure", "type": "PROCEDURE" }, { "name": "antibody therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "colony-stimulating factor therapy", "type": "PROCEDURE" }, { "name": "cytokine therapy", "type": "PROCEDURE" }, { "name": "monoclonal antibody therapy", "type": "PROCEDURE" }, { "name": "non-specific immune-modulator therapy", "type": "PROCEDURE" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "tumor cell derivative vaccine", "type": "PROCEDURE" }, { "name": "vaccine therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Favrille", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 2, "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324831" }, { "nct_id": "NCT04484623", "title": "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2020-10-01", "completion_date": "2029-06-25", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 5, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484623" }, { "nct_id": "NCT06265727", "title": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "CRB-701", "type": "DRUG" }, { "name": "Anti-PD-1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 348, "start_date": "2024-04-01", "completion_date": "2027-01-27", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-11-08T03:52:29.443Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265727" } ] }